Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma

Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Med
Prif Awduron: Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf‐Henrik, Nahi, Hareth
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2018
Pynciau:
Clinical Cancer Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010717/
https://ncbi.nlm.nih.gov/pubmed/29673108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1422
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg